Cancer clinical trials in the region Île-de-France
732 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Breast cancer
#NCT05439005
#2024-513308-32-00
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
3 recruiting sites
Institut Curie
Phase 3
Breast cancer
#NCT07060807
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
1
Required previous treatments at advanced or metastatic stage
Targeted therapy
Hormone therapy
Excluded genetic anomalies
BRCA 1/2
Excluded previous treatments at advanced or metastatic stage
Chemotherapy
4 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Acute leukemia
#NCT07504458
#2025-524810-28-00
Required histologic types
Other acute leukemia
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
2 recruiting sites
Quetzal Therapeutics
Phase 3
Acute leukemia
#NCT06652438
#2024-512733-32-00
Required histologic types
Acute myeloid leukemia (AML)
Required genetic anomalies
KMT2A
NPM1
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
BCR-ABL
8 recruiting sites
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
Breast cancer
#NCT07205822
#2025-521904-23-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Chemotherapy
5 recruiting sites
AstraZeneca
Phase 3
Prostate cancer
#NCT06136624
#2023-504899-25-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Amyloidosis
#NCT07052903
#2024-519917-72-00
Required histologic types
Other
Required organ involvement status
Presence
Required organ involvements
Cardiac
15 recruiting sites
Alnylam Pharmaceuticals
Phase 3
Prostate cancer
#NCT06136650
#2023-504957-11-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Internal Vectorised Radiotherapy (IVR)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Internal Vectorised Radiotherapy (IVR)
9 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Lung cancer
#NCT07144280
#2025-521281-97-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
12 recruiting sites
Pfizer
Phase 3
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT07218809
#2025-520466-22-00
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required platino resistance
Recurrence within 6 months after platinum-based tr...
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
AstraZeneca